Filing Analysis
Actinium Pharmaceuticals, Inc. has submitted a compliance plan to the NYSE American to address a deficiency in stockholders' equity requirements. The company is currently non-compliant with listing standards due to failing to maintain at least $4.0 million in stockholders' equity.
🚩 Red Flags
- Delisting risk due to non-compliance with NYSE American listing standards.
- Failure to maintain minimum stockholders' equity ($4.0M requirement).
- History of net losses in three of the last four fiscal years, indicating potential liquidity or capital structure issues.
📋 Key Facts
- The Company received a notice of non-compliance from NYSE American on May 27, 2026.
- Non-compliance is specifically related to Section 1003(a)(ii) of the NYSE American Company Guide regarding stockholders' equity requirements.
- The deficiency stems from reporting losses in three of its four most recent fiscal years and failing to maintain $4.0 million in stockholders' equity.
- A compliance plan was submitted to the exchange on June 18, 2026.
Actinium Pharmaceuticals received a notice from NYSE American on May 27, 2026, stating it is not in compliance with continued listing standards due to insufficient stockholders' equity. The company must submit a compliance plan by June 26, 2026, to avoid delisting proceedings.
🚩 Red Flags
- Stockholders' equity ($2.3M) is significantly below the $4.0M requirement.
- Chronic losses over the last five consecutive fiscal years.
- Multiple 8-K items (3.01, 7.01, 9.01) in a single filing.
- Risk of delisting if the plan is rejected or not implemented successfully.
📋 Key Facts
- Company failed to maintain the minimum stockholders' equity requirement of $4.0 million.
- As of March 31, 2026, reported stockholders' equity was approximately $2.3 million.
- The company has reported net losses in its last five fiscal years ended December 31, 2025.
- Deadline to submit a compliance plan to NYSE American is June 26, 2026.
- If a plan is accepted, the deadline to regain compliance is November 27, 2027.
- Common stock will now trade with a '.BC' indicator to denote non-compliance.
Actinium Pharmaceuticals filed an amendment to a previous 8-K to disclose the Board's decision regarding the frequency of 'Say-on-Pay' advisory votes. The company has decided to conduct these votes annually, aligning with the preference expressed by shareholders during the November 26, 2025, Annual Meeting.
📋 Key Facts
- The filing is an Amendment (8-K/A) to a report originally filed on November 26, 2025.
- Shareholders expressed a preference for annual 'Say-on-Pay' votes during the Annual General Meeting.
- On March 20, 2026, the Board of Directors formally determined that future Say-on-Pay votes will be conducted every year.
- The Board will re-evaluate this frequency after the next advisory vote, slated for the 2031 Annual General Meeting unless presented earlier.
Actinium Pharmaceuticals announced the resignation of CFO Steve O’Loughlin, effective February 27, 2026. To fill the vacancy, CEO Sandesh Seth will assume the role of Principal Financial Officer on the same effective date.
🚩 Red Flags
- Dual role: The CEO is assuming the CFO responsibilities, which can indicate a lack of immediate succession depth or resource constraints.
- Concentration of control/responsibility in a single individual (CEO acting as PFO).
📋 Key Facts
- CFO Steve O’Loughlin resigned to pursue other opportunities; resignation is not due to disagreements with the Company.
- Effective Date for departure and transition: February 27, 2026.
- CEO Sandesh Seth will serve as Principal Financial Officer effective February 27, 2026.
- Sandesh Seth has been CEO since June 2017 and Chairman since October 2013.
Actinium Pharmaceuticals, Inc. held its 2025 annual meeting of stockholders on November 26, 2025. All proposals were approved, including the election of two Class III directors and the ratification of the company's independent auditor.
🚩 Red Flags
- High number of 'Broker Non-Votes' across all items suggests significant portion of shares are held by institutional/non-voting beneficial owners or were not instructed.
📋 Key Facts
- Annual Meeting held on November 26, 2025.
- Ajit S. Shetty elected as Class III director (term expiring at 2028 Annual Meeting).
- June S. Almenoff elected as Class III director (term expiring at 2028 Annual Meeting).
- CBIZ ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- Stockholders approved a non-binding advisory vote on executive compensation frequency set to 3 years.
- Total shares present/represented: 15,494,573 out of 31,195,891 outstanding (approx. 49.6% quorum).
Actinium Pharmaceuticals, Inc. has dismissed Marcum LLP as its independent registered public accounting firm following the acquisition of Marcum's attest business by CBIZ CPAs P.C. The company has engaged CBIZ CPAs P.C. as its new auditor for the fiscal year ending December 31, 2025.
🚩 Red Flags
- None identified; the change is due to a business acquisition by the previous auditor's parent entity rather than an internal dispute.
📋 Key Facts
- Dismissal of Marcum LLP effective May 08, 2025.
- Reason for dismissal: Marcum's attest business was acquired by CBIZ CPAs P.C. on November 1, 2024.
- Engagement of CBIZ CPAs P.C. as the new independent registered public accounting firm effective May 08, 2025.
- The company confirmed there were no disagreements with Marcum regarding accounting principles or auditing procedures for fiscal years 2023 and 2024.
Actinium Pharmaceuticals, Inc. held its 2024 annual meeting of stockholders on November 27, 2024. The company successfully elected two Class II directors and ratified the appointment of its independent auditor.
📋 Key Facts
- Annual Meeting held on November 27, 2024.
- Sandesh Seth was elected as a Class II director (term expiring at 2027 Annual Meeting).
- Jeffrey W. Chell was elected as a Class II director (term expiring at 2027 Annual Meeting).
- Stockholders ratified the appointment of Marcum LLP as the independent registered public accounting firm for fiscal year ending December 31, 2024.
- Total shares present or represented by proxy: 19,724,287 out of 31,195,891 outstanding (approx. 63% quorum/participation).
Actinium Pharmaceuticals, Inc. announced the appointment of June Almenoff, M.D., Ph.D., to its Board of Directors and the Nominating and Corporate Governance Committee effective November 1, 2024.
📋 Key Facts
- Dr. June Almenoff appointed as a Class III director on November 1, 2024.
- Appointed to serve on the Nominating and Corporate Governance Committee.
- Granted 50,000 stock options with an exercise price of $1.71 per share.
- Vesting schedule: 28% after 12 months, then 2% monthly until fully vested.
Actinium Pharmaceuticals, Inc. issued a press release regarding a regulatory update concerning its planned Biologics License Application (BLA) for Iomab-B in treating relapsed or refractory acute myeloid leukemia (r/r AML). The filing is made under Item 7.01 to provide information via Regulation FD.
📋 Key Facts
- The company announced a regulatory update regarding its planned BLA filing for Iomab-B.
- Target indication: Patients with active relapsed or refractory acute myeloid leukemia (r/r AML).
- Filing date: August 5, 2024.